| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/14/2011 | CA2443325C Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
| 06/14/2011 | CA2437966C 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical |
| 06/14/2011 | CA2436421C Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same |
| 06/14/2011 | CA2433667C Prodrugs of excitatory amino acids |
| 06/14/2011 | CA2430669C Synthesis of 3-amino-thalidomide and its enantiomers |
| 06/14/2011 | CA2428468C New 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them |
| 06/14/2011 | CA2426292C Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression |
| 06/14/2011 | CA2425311C Ketone compounds and compositions for cholesterol management and related uses |
| 06/14/2011 | CA2416673C Heparin-derived polysaccharide mixtures, preparation method and pharmaceutical compositions containing same |
| 06/14/2011 | CA2413313C Antitumor effect potentiators |
| 06/14/2011 | CA2405787C Method for preparing microparticles having a selected polymer molecular weight |
| 06/14/2011 | CA2400888C Bifunctional chelating agent |
| 06/14/2011 | CA2399482C Method for classifying and treating physiologic brain imbalances using quantitative eeg |
| 06/14/2011 | CA2349490C Antimicrobial composition comprising an oxidoreductase and an enhancing agent of the n-hydroxyanilide-type |
| 06/14/2011 | CA2338419C Pulmonary delivery of active agents |
| 06/14/2011 | CA2337205C Treatment of skin disorders |
| 06/14/2011 | CA2328159C Use of aminoalkylphosphonic acid derivatives for the therapeutic and preventative treatment of infections |
| 06/14/2011 | CA2222630C Material inhibiting lipid peroxide-increase |
| 06/14/2011 | CA2200540C Use of l-carnitine or derivatives thereof and antioxidants for the prevention and treatment of diseases elicited by oxidative stress to the nervous and cardiovascular system |
| 06/14/2011 | CA2182621C Galanin receptor, nucleic acids, transformed cells and uses thereof |
| 06/09/2011 | WO2011069159A2 Bis[thiohydrazide amide] compounds for treating leukemia |
| 06/09/2011 | WO2011069149A2 Cathepsin s inhibitors |
| 06/09/2011 | WO2011069141A2 Interferon therapies in combination with blockade of stat3 activation |
| 06/09/2011 | WO2011069118A1 Ship1 modulators and methods related thereto |
| 06/09/2011 | WO2011069094A1 Methods of administering pirfenidone therapy |
| 06/09/2011 | WO2011069089A1 Pirfenidone therapy and inducers of cytochrome p450 |
| 06/09/2011 | WO2011069076A2 Sustained release donepezil formulations |
| 06/09/2011 | WO2011069063A2 Multicyclic compounds and methods of use thereof |
| 06/09/2011 | WO2011069053A1 Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl |
| 06/09/2011 | WO2011069051A1 Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions |
| 06/09/2011 | WO2011069045A2 Synthesis of syrbactin proteasome inhibitors |
| 06/09/2011 | WO2011069039A1 Hydrazone and diacyl hydrazine compounds and methods of use |
| 06/09/2011 | WO2011069032A2 Formulations, salts and polymorphs of transnorsertraline and uses thereof |
| 06/09/2011 | WO2011069010A2 Amantadine compositions and methods of use |
| 06/09/2011 | WO2011069002A1 Organoselenium compounds and uses thereof |
| 06/09/2011 | WO2011068990A1 Compositions and methods for inhibiting dyrk1a to treat central nervous system diseases and disorders |
| 06/09/2011 | WO2011068987A2 Compositions and methods for the treatment of giardiasis |
| 06/09/2011 | WO2011068978A1 Methanocarba adenosine derivatives and dendrimer conjugates thereof |
| 06/09/2011 | WO2011068941A2 Proline derivatives |
| 06/09/2011 | WO2011068934A2 Vaccine against neoplastic or cancerous lesions caused by human papillomavirus (hpv), procedures, uses and methods |
| 06/09/2011 | WO2011068927A2 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF |
| 06/09/2011 | WO2011068926A1 Iap inhibitors |
| 06/09/2011 | WO2011068923A1 Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
| 06/09/2011 | WO2011068899A1 Novel tricyclic compounds |
| 06/09/2011 | WO2011068898A1 Protein kinase c inhibitors and uses thereof |
| 06/09/2011 | WO2011068897A1 Method for removing cytokines from blood with surface immobilized polysaccharides |
| 06/09/2011 | WO2011068876A1 Compounds for the treatment of ocular cancer |
| 06/09/2011 | WO2011068863A1 Combination therapy for treating cancer and diagnostic assays for use therein |
| 06/09/2011 | WO2011068821A1 Benzimidazole inhibitors of leukotriene production |
| 06/09/2011 | WO2011068810A1 Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| 06/09/2011 | WO2011068786A2 Treating xerophthalmia with compounds increasing meibomian gland secretion |
| 06/09/2011 | WO2011068723A1 Abuse resistant melt extruded formulation having reduced alcohol interaction |
| 06/09/2011 | WO2011068722A1 Transdermal testosterone device and delivery |
| 06/09/2011 | WO2011068721A1 Hypersulfated disaccharide formulations |
| 06/09/2011 | WO2011068715A1 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections |
| 06/09/2011 | WO2011068703A2 Methods of modulating inflammation in preterm infants using carotenoids |
| 06/09/2011 | WO2011068702A1 Soy protein-based nutritional formula with superior stability |
| 06/09/2011 | WO2011068667A1 Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
| 06/09/2011 | WO2011068563A1 Uses of hypoxia-inducible factor inhibitors |
| 06/09/2011 | WO2011068561A1 Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| 06/09/2011 | WO2011068546A2 Prognosis, diagnosis and identification of multiple myeloma based on global gene expression profiling |
| 06/09/2011 | WO2011068455A1 Microspheres of hydrolysed starch with endogenous, charged ligands |
| 06/09/2011 | WO2011068404A2 Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation |
| 06/09/2011 | WO2011068403A2 Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts |
| 06/09/2011 | WO2011068386A2 Anticancer composition containing a kampheride compound as an active ingredient |
| 06/09/2011 | WO2011068303A2 Hyaluronic acid derivative effective against atopic dermatitis, and method for manufacturing same |
| 06/09/2011 | WO2011068288A1 Agent for prevention or treatment of benign prostatic hyperplasia comprising a quinazoline derivative |
| 06/09/2011 | WO2011068233A1 Imidazoquinolines which act via toll - like receptors (tlr) |
| 06/09/2011 | WO2011068226A1 Macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages |
| 06/09/2011 | WO2011068211A1 2-pyridone compounds |
| 06/09/2011 | WO2011068208A1 Therapeutic agent for spinal and bulbar muscular atrophy |
| 06/09/2011 | WO2011068187A1 Quinazoline derivatives |
| 06/09/2011 | WO2011068171A1 Bicyclic nitrogen-containing saturated heterocyclic derivatives |
| 06/09/2011 | WO2011067693A1 Compositions comprising nonsteroidal anti - inflammatory drugs |
| 06/09/2011 | WO2011067663A1 Pharmaceutical preparations comprising phloroglucinol and/or derivatives thereof and some non-steroidal anti-inflammatory drugs and their use in the treatment and/or prevention of pain syndromes of the feminine genital system |
| 06/09/2011 | WO2011067653A1 Oral compositions for use in the mercury intoxication from dental amalgam |
| 06/09/2011 | WO2011067608A1 Treatment of allodynia and hyperalgesia |
| 06/09/2011 | WO2011067607A1 Treatment of infectious diseases |
| 06/09/2011 | WO2011067571A1 Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor |
| 06/09/2011 | WO2011067560A1 Combination of droloxifene and clopidogrel |
| 06/09/2011 | WO2011067544A1 Diphenyl-pyrazolopyrdine derivatives, preparation thereof, and use thereof as nuclear receptor not modulators |
| 06/09/2011 | WO2011067501A1 Local topical application aminosteroid compounds for mucous/cutaneous decolonization of staphylococcus aureus |
| 06/09/2011 | WO2011067403A1 Starch derivative mixtures |
| 06/09/2011 | WO2011067366A1 Indazole derivatives as pi 3 - kinase inhibitors |
| 06/09/2011 | WO2011067365A1 Benzpyrazole derivatives as inhibitors of p13 kinases |
| 06/09/2011 | WO2011067364A1 Novel compounds |
| 06/09/2011 | WO2011067317A1 Pharmaceutical compositions for the stimulation of stem cells. |
| 06/09/2011 | WO2011067302A1 Topical use of hydroxytyrosol and derivatives for the prevention of hiv infection |
| 06/09/2011 | WO2011067236A2 Raltegravir polymorphs |
| 06/09/2011 | WO2011067225A1 Compositions targeting cb1 receptor for controlling food intake |
| 06/09/2011 | WO2011067220A1 A process for the purification of paliperidone |
| 06/09/2011 | WO2011067219A1 Diphenyl azepine derivatives as monoamine reuptake inhibitors |
| 06/09/2011 | WO2011067212A1 Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
| 06/09/2011 | WO2011067185A1 Spiroindolinone pyrrolidines |
| 06/09/2011 | WO2011067174A1 Aniline analogs as glycogen synthase activators |
| 06/09/2011 | WO2011067166A1 Azacyclic spiro derivatives |
| 06/09/2011 | WO2011067145A1 Tricyclopyrazole derivatives |
| 06/09/2011 | WO2011066980A2 Oral dosage forms with reduced potential for drug abuse |
| 06/09/2011 | WO2011066949A1 Suppository for rectal, vaginal or urethral administration containing a probiotic, an antibiotic and an unsaturated non- esterified fatty acid |
| 06/09/2011 | WO2011066864A1 Method and compositions for inhibition of macrophage migration inhibitory factor (mif) |